Back to all studies
🎗️
Phase 2
Oncology
in-person
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Sponsored by Hoffmann-La Roche
Compensation
$500–$2,500
Duration
3 months
Location
Nationwide
About this study
This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).
Who can participate
- • Adults aged 18–99
- • Female only
- • Diagnosed with or experiencing breast cancer
- • Able to attend in-person clinic visits
What's included
- • Compensation up to $2,500
- • All study-related medical care at no cost
- • Lab work, screenings, and physician consultations
- • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.
Ready to Find a Paid Study?
Join over 100,000 people who have been matched with clinical studies. It's free, fast, and could change your life.